JPH1084909A - Intestinal butyric acid concentration increase accelerating agent - Google Patents
Intestinal butyric acid concentration increase accelerating agentInfo
- Publication number
- JPH1084909A JPH1084909A JP8263731A JP26373196A JPH1084909A JP H1084909 A JPH1084909 A JP H1084909A JP 8263731 A JP8263731 A JP 8263731A JP 26373196 A JP26373196 A JP 26373196A JP H1084909 A JPH1084909 A JP H1084909A
- Authority
- JP
- Japan
- Prior art keywords
- butyric acid
- intestinal
- acid concentration
- bifidobacterium longum
- lactobacillus acidophilus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 title abstract description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 36
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 36
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 31
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 241001608472 Bifidobacterium longum Species 0.000 claims description 38
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 38
- 230000001737 promoting effect Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 5
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000002881 Colic Diseases 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 239000000843 powder Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WLDRFJDGKMTPPV-UHFFFAOYSA-N 1,2-dimethylhydrazine dihydrochloride Chemical compound Cl.Cl.CNNC WLDRFJDGKMTPPV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000011833 salt mixture Substances 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- 235000019944 Olestra Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000061184 Phyllobacteriaceae bacterium Species 0.000 description 1
- -1 Polyethylene Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940054333 biotin 2 mg Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- VDHMTEHMHQZPCU-UHFFFAOYSA-J dicopper;carbonate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Cu+2].[Cu+2].[O-]C([O-])=O VDHMTEHMHQZPCU-UHFFFAOYSA-J 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LPASYNDWGGXOKH-UHFFFAOYSA-L disodium selenate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-][Se]([O-])(=O)=O LPASYNDWGGXOKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940106305 folic acid 20 mg Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- ALRLJVYQOIVNRH-UHFFFAOYSA-N iodic acid;potassium Chemical compound [K].OI(=O)=O ALRLJVYQOIVNRH-UHFFFAOYSA-N 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- OQTQHQORDRKHFW-UHFFFAOYSA-L manganese(2+);sulfate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O OQTQHQORDRKHFW-UHFFFAOYSA-L 0.000 description 1
- SCVOEYLBXCPATR-UHFFFAOYSA-L manganese(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O SCVOEYLBXCPATR-UHFFFAOYSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- ZFVHBEKVAITXHW-UHFFFAOYSA-J potassium;chromium(3+);disulfate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[K+].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZFVHBEKVAITXHW-UHFFFAOYSA-J 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、新規な腸内酪酸濃
度上昇促進剤ならびに腸内酪酸濃度上昇促進作用を賦与
した飲食品及び飼料に関する。TECHNICAL FIELD The present invention relates to a novel intestinal butyric acid concentration-enhancing agent and to foods, drinks and feeds which have an intestinal butyric acid concentration-enhancing effect.
【０００２】[0002]
【従来の技術】近年、腸内発酵により生成される短鎖脂
肪酸が注目されてきている(Cummings,J.H., Rombeau,J.
L. and Sakata,T., Physiological and Clinical Aspec
ts ofShort-Chain Fatty Acids, Cambridge University
Press, 1995)。腸内の短鎖脂肪酸は、食事として摂取
されたオリゴ糖や食物繊維が消化されずに盲腸や大腸に
達して腸内細菌に利用されることにより生成し、この生
成した短鎖脂肪酸は速やかに腸管から吸収される。この
短鎖脂肪酸の主要な構成成分は、酢酸、プロピオン酸及
び酪酸である。酢酸は主に筋肉の熱源として利用され、
プロピオン酸は肝臓においてコレステロールや炭水化物
の代謝調節に関与していると考えられている。また、酪
酸は大腸の上皮細胞にとって重要な物質である。酪酸は
大腸上皮細胞に作用して細胞分化や遺伝子の発現等を修
飾することにより、大腸上皮細胞の構造や機能を維持す
る上で重要な役割を果たすと考えれている。そして、こ
のことは、酪酸が大腸癌や潰瘍性大腸炎の予防に重要で
あることを示唆している。2. Description of the Related Art In recent years, short-chain fatty acids produced by intestinal fermentation have attracted attention (Cummings, JH, Rombeau, J. et al.
L. and Sakata, T., Physiological and Clinical Aspec
ts ofShort-Chain Fatty Acids, Cambridge University
Press, 1995). Short-chain fatty acids in the intestine are produced when oligosaccharides and dietary fiber taken as a meal reach the cecum and large intestine without being digested and are used by intestinal bacteria. Is absorbed from the intestinal tract. The major components of this short chain fatty acid are acetic, propionic and butyric acids. Acetic acid is mainly used as a heat source for muscles,
Propionic acid is thought to be involved in the regulation of cholesterol and carbohydrate metabolism in the liver. Butyric acid is an important substance for epithelial cells of the large intestine. Butyric acid is thought to play an important role in maintaining the structure and function of colorectal epithelial cells by acting on colorectal epithelial cells to modify cell differentiation and gene expression. And this suggests that butyric acid is important for prevention of colorectal cancer and ulcerative colitis.
【０００３】一方、ある種のオリゴ糖や食物繊維を摂取
することにより、腸内の酪酸濃度が上昇することが報告
されている。オリゴ糖の一種であるラクチトール・オリ
ゴ糖を実験飼料に５％レベルで添加し、ラットに３週間
摂取させた報告では、盲腸内容物に含まれる酪酸の濃度
が上昇している(Yanahira,S., Morita,M., Aoe,S., Sug
uri,T., Nakajima,I. and Deya,E., Journal of Nutrit
ional Science and Vitaminology, vol.41, pp.83-94,
1995) 。また、食物繊維の一種であるイヌリンを実験飼
料に11.6％レベルで添加し、ヒトの糞便内細菌を定住さ
せたラットに６週間摂取させた報告(Roland,N., Nugon-
Baudon,L., Andrieux,C.and Szylit,O.,British Journa
l of Nutrition, vol.74, pp.239-249, 1995)、並びに
オリゴ糖と食物繊維の中間的な物質であるグアガム部分
水解物を実験飼料に５％レベルで添加し、ラットに２週
間摂取させた報告（竹久文之, 日本栄養・食糧学会誌,
vol.45, pp.325-331, 1992) においても、盲腸内容物に
含まれる酪酸の濃度が上昇している。さらに、ショ糖の
ポリエステルであり、脂肪代替物であるオレストラを１
日当たり 24gヒトに４週間摂取させた報告(Siigur,U.,
Norin,K.E., Allgood,G., Schlagheck,T. and Midtved
t,T., Microbial Ecology in Health and Disease, vo
l.9, pp.9-17, 1996) においても、糞便中の酪酸濃度が
上昇している。しかし、これらのオリゴ糖や食物繊維を
摂取することにより腸内の酪酸濃度を上昇させるために
は、多量にオリゴ糖や食物繊維を摂取することが必要で
あるという問題があった。On the other hand, it has been reported that ingestion of certain oligosaccharides and dietary fiber increases butyric acid concentration in the intestine. According to a report in which lactitol / oligosaccharide, a kind of oligosaccharide, was added to experimental feed at a level of 5% and the rats were ingested for 3 weeks, the concentration of butyric acid contained in cecal contents was increased (Yanahira, S. et al. , Morita, M., Aoe, S., Sug
uri, T., Nakajima, I. and Deya, E., Journal of Nutrit
ional Science and Vitaminology, vol.41, pp.83-94,
1995). In addition, inulin, a kind of dietary fiber, was added to experimental feed at a level of 11.6%, and rats settled with human fecal bacteria were ingested for 6 weeks (Roland, N., Nugon-
Baudon, L., Andrieux, C.and Szylit, O., British Journa
l of Nutrition, vol. 74, pp. 239-249, 1995), and guar gum partial hydrolyzate, an intermediate substance between oligosaccharides and dietary fiber, was added to experimental feed at a level of 5%, and fed to rats for 2 weeks. Report (Fumiyuki Takehisa, Journal of Japanese Society of Nutrition and Food,
vol.45, pp.325-331, 1992), the concentration of butyric acid contained in the cecal contents is increasing. In addition, Olestra, a sucrose polyester and a fat substitute,
A report of 24 g human being ingested for 4 weeks per day (Siigur, U.,
Norin, KE, Allgood, G., Schlagheck, T. And Midtved
t, T., Microbial Ecology in Health and Disease, vo
l.9, pp.9-17, 1996), butyric acid concentration in feces is also increasing. However, in order to increase the intestinal butyric acid concentration by ingesting these oligosaccharides and dietary fibers, there is a problem that it is necessary to ingest a large amount of oligosaccharides and dietary fibers.
【０００４】[0004]
【発明が解決しようとする課題】本発明者らは、食生活
を大きく変えることなく、安全で安価に提供が可能な腸
内酪酸濃度の上昇を促進する物質を求めて鋭意研究を進
めてきたところ、従来より食用に供され安全性が立証さ
れている腸内細菌であるラクトバチルス・アシドフィル
ス(Lactobacillus acidophilus)やビフィドバクテリウ
ム・ロンガム(Bifidobacterium longum) の菌体に腸内
酪酸濃度の上昇を促進する作用があることを見出し、本
発明を完成するに至った。したがって、本発明は、新規
な腸内酪酸濃度上昇促進剤ならびにこのような腸内酪酸
濃度上昇促進作用が賦与された飲食品及び飼料を提供す
ることを課題とする。さらに詳しくは、本発明は、ラク
トバチルス・アシドフィルス(Lactobacillus acidophi
lus)及び／又はビフィドバクテリウム・ロンガム(Bifid
obacterium longum) の菌体を有効成分とする腸内酪酸
濃度上昇促進剤を提供することを課題とする。また、本
発明は、ラクトバチルス・アシドフィルス(Lactobacill
us acidophilus)及び／又はビフィドバクテリウム・ロ
ンガム(Bifidobacterium longum) の菌体を配合して腸
内酪酸濃度上昇促進作用を賦与した飲食品及び飼料を提
供することを課題とする。DISCLOSURE OF THE INVENTION The present inventors have intensively studied a substance which promotes an increase in intestinal butyric acid concentration which can be safely and inexpensively provided without largely changing the diet. However, Lactobacillus acidophilus (Lactobacillus acidophilus) and Bifidobacterium longum (Bifidobacterium longum ), which are edible bacteria that have been conventionally used for food and whose safety has been proved, have been shown to enter the intestines. The present inventors have found that the compound has an effect of promoting an increase in butyric acid concentration, and have completed the present invention. Therefore, an object of the present invention is to provide a novel intestinal butyric acid concentration increase promoter, and a food, beverage, and feed provided with such an intestinal butyric acid concentration increase promoting effect. More specifically, the present invention relates to Lactobacillus acidophi
lus) and / or Bifidobacterium longum (Bifid
It is an object of the present invention to provide an intestinal butyric acid concentration increase promoter comprising a bacterium of P. bacterium longum ) as an active ingredient. The present invention also relates to Lactobacillus acidophilus (Lactobacill
us acidophilus) and / or Bifidobacterium longum (Bifidobacterium longum ) to provide foods and drinks and feeds having an intestinal butyric acid concentration increasing promoting effect. .
【０００５】[0005]
【課題を解決するための手段】本発明の腸内酪酸濃度上
昇促進剤、飲食品及び飼料は、その有効成分として、ラ
クトバチルス・アシドフィルス(Lactobacillus acidop
hilus)及び／又はビフィドバクテリウム・ロンガム(Bif
idobacterium longum) の菌体を有効成分として使用す
る。なお、本発明で使用することのできるラクトバチル
ス・アシドフィルス(Lactobacillus acidophilus)とし
ては、ラクトバチルス・アシドフィルス(Lactobacillus
acidophilus) SBT-2062 (FERM P-10730)等の菌株を例
示することができ、また、ビフィドバクテリウム・ロン
ガム(Bifidobacterium longum)としては、ビフィドバ
クテリウム・ロンガム(Bifidobacterium longum) SBT-
2928 (FERM P-10657) 等の菌株を例示することができ
る。Means for Solving the Problems The intestinal butyric acid concentration-increasing promoter, foods and drinks and feeds of the present invention comprise, as an active ingredient, Lactobacillus acidopils.
hilus) and / or Bifidobacterium longum (Bif
idobacterium longum ) is used as an active ingredient. Incidentally, Lactobacillus acidophilus (Lactobacillus acidophilus) that can be used in the present invention, Lactobacillus acidophilus (Lactobacillus
acidophilus) SBT-2062 (can be exemplified FERM P-10730) strain etc., As the Bifidobacterium Ron <br/> gum (Bifidobacterium longum), Bifidobacterium longum (Bifidobacterium longum ) SBT-
Bacteria such as 2928 (FERM P-10657) can be exemplified.
【０００６】次に、ラクトバチルス・アシドフィルス(L
actobacillus acidophilus)及びビフィドバクテリウム
・ロンガム(Bifidobacterium longum) 菌体の腸内酪酸
濃度上昇促進作用について説明する。Next, Lactobacillus acidophilus (L
The action of the cells of actobacillus acidophilus and Bifidobacterium longum to increase the intestinal butyric acid concentration will be described.
【０００７】[0007]
【参考例１】表１に示した組成の培地 12Lに、ラクトバ
チルス・アシドフィルス(Lactobacillus acidophilus)
SBT-2062 (FERM P-10730)の前培養物５重量％を接種
し、37℃で16時間循環培養して菌を増殖させた。Reference Example 1 Lactobacillus acidophilus (Lactobacillus acidophilus) was added to 12 L of a medium having the composition shown in Table 1.
5% by weight of a preculture of SBT-2062 (FERM P-10730) was inoculated and circulated at 37 ° C. for 16 hours to grow the bacteria.
【０００８】[0008]
【表１】 ────────────────────────────── Ｄ−グルコース 20 (g/L) プロテオース・ペプトン 10 酵母エキス粉末 10 酢酸ナトリウム・３水和物 5 クエン酸水素２アンモニウム 5 リン酸水素２カリウム 5 リン酸２水素カリウム 1 ポリエチレン（２０）ソルビタン モノオレイト 1 Ｌ−アスコルビン酸ナトリウム 1 塩化カルシウム 0.2 硫酸マグネシウム・６水和物 0.2 硫酸マンガン・７水和物 0.054 ──────────────────────────────[Table 1] D-glucose 20 (g / L) Proteose / Peptone 10 Yeast extract powder 10 Sodium acetate trihydrate 5 Ammonium hydrogen citrate 5 Potassium hydrogen phosphate 5 Potassium dihydrogen phosphate 1 Polyethylene (20) sorbitan monooleate 1 Sodium L-ascorbate 1 Calcium chloride 0.2 Magnesium sulfate hexahydrate 0.2 Manganese sulfate heptahydrate 0.054──────────────────────────────
【０００９】培養終了後、 0.9％塩化ナトリウム溶液 6
0Lを循環して菌体を洗浄した。この培養液を限外濾過膜
で処理して7Lとなるまで濃縮した後、４℃で遠心分離
(4,500×g 、15分間) を行うことにより、菌体を含むス
ラリーを回収した。そして、菌体を含むスラリーには、
凍結保護剤としてグルタミン酸ナトリウムとショ糖を最
終濃度がそれぞれ１％及び５％となるよう添加し、溶解
した後、凍結乾燥し、ラクトバチルス・アシドフィルス
(Lactobacillus acidophilus)の菌体粉末 50gを得た。
なお、この菌体粉末中の生菌数は４×1011cfu/g であっ
た。After completion of the culture, a 0.9% sodium chloride solution 6
The cells were washed by circulating 0 L. This culture solution is treated with an ultrafiltration membrane, concentrated to 7 L, and then centrifuged at 4 ° C.
(4,500 × g, 15 minutes) to recover a slurry containing bacterial cells. And in the slurry containing the cells,
Sodium glutamate and sucrose were added as cryoprotectants to a final concentration of 1% and 5%, respectively, dissolved, lyophilized, and lactobacillus acidophilus.
(Lactobacillus acidophilus) 50 g of bacterial cell powder was obtained.
The viable cell count in this cell powder was 4 × 10 11 cfu / g.
【００１０】[0010]
【参考例２】表２に示した組成の培地 12Lに、ビフィド
バクテリウム・ロンガム(Bifidobacterium longum) SB
T-2928 (FERM P-10657) の前培養物５重量％を接種し、
37℃で16時間循環培養して菌を増殖させた。なお、培養
に際しては、6Nアンモニア溶液を断続的に添加して培地
のpHが 6.5になるように調整した。[Reference Example 2] Bifidobacterium longum (Bifidobacterium longum ) SB was added to 12 L of medium having the composition shown in Table 2.
Inoculated with 5% by weight of a preculture of T-2928 (FERM P-10657),
The bacteria were grown by circulating culture at 37 ° C. for 16 hours. During the culture, the pH of the medium was adjusted to 6.5 by intermittently adding a 6N ammonia solution.
【００１１】[0011]
【表２】 ─────────────────────── プロテオース・ペプトン 10 (g/L) 酵母エキス粉末 10 Ｄ−グルコース 10 リン酸水素２カリウム 5 リン酸２水素カリウム 1 Ｌ−アスコルビン酸ナトリウム 1 ───────────────────────[Table 2] テ Proteose peptone 10 (g / L) Yeast extract powder 10 D-glucose 10 Dipotassium hydrogen phosphate 5 Potassium dihydrogen phosphate 1 L-sodium ascorbate 1───────────────────────
【００１２】培養終了後、 0.9％塩化ナトリウム溶液 6
0Lを循環して菌体を洗浄した。この培養液を限外濾過膜
で処理して7Lとなるまで濃縮した後、４℃で遠心分離
(8,000×g 、15分間) を行うことにより、菌体を含むス
ラリーを回収した。そして、菌体を含むスラリーには、
凍結保護剤としてグルタミン酸ナトリウムとショ糖を最
終濃度がそれぞれ１％及び５％となるよう添加し、溶解
した後、凍結乾燥し、ビフィドバクテリウム・ロンガム
(Bifidobacterium longum) の菌体粉末 80gを得た。な
お、この菌体粉末中の生菌数は３×1011cfu/g であっ
た。After completion of the culture, a 0.9% sodium chloride solution 6
The cells were washed by circulating 0 L. This culture solution is treated with an ultrafiltration membrane, concentrated to 7 L, and then centrifuged at 4 ° C.
(8,000 × g, 15 minutes) to recover a slurry containing bacterial cells. And in the slurry containing the cells,
Sodium glutamate and sucrose were added as cryoprotectants to a final concentration of 1% and 5%, respectively, dissolved, freeze-dried, and Bifidobacterium longum.
80 g of (Bifidobacterium longum ) bacterial cell powder was obtained. The viable cell count in this cell powder was 3 × 10 11 cfu / g.
【００１３】[0013]
【試験例１】 （１）実験動物の飼育 動物実験は以下のようにして行った。すなわち、８週齢
のWistar系雄ラット24匹に、代謝活性化により大腸癌を
発症させる１，２−ジメチルヒドラジン・２塩酸を体重
１kg当たり40mgとなるように調製して皮下注射した。な
お、実験動物に１，２−ジメチルヒドラジン・２塩酸を
注射すると大腸癌を発病し易い遺伝的素因が誘導される
という報告がなされている(Lipkin,M., Blattner,W.E.,
Fraumeni,J.F.Jr., Lynch,H.T., Deschner,E. and Win
awer,S., Cancer Research, vol.43, pp.1899-1904, 19
93) 。Test Example 1 (1) Breeding of Experimental Animals Animal experiments were performed as follows. Specifically, 24 8-week-old male Wistar rats were subcutaneously injected with 40 mg / kg body weight of 1,2-dimethylhydrazine dihydrochloride, which causes colorectal cancer by metabolic activation. In addition, it has been reported that injection of 1,2-dimethylhydrazine dihydrochloride into experimental animals induces a genetic predisposition that is likely to cause colorectal cancer (Lipkin, M., Blattner, WE,
Fraumeni, JFJr., Lynch, HT, Deschner, E. and Win
awer, S., Cancer Research, vol.43, pp.1899-1904, 19
93).
【００１４】これらのラットを群間にて体重が等しくな
るよう配慮しながら１群８匹の３群に分け、表３に示し
た実験飼料を15日間自由摂取させた。また、イオン交換
水も自由摂取させた。なお、対照飼料及び実験飼料に配
合した脂肪量は、標準飼料(American Institute of Nut
rition, Journal of Nutrition, vol.107, pp.1340-134
8, 1977)の４倍であり、カルシウム量は１／５である。
なお、実験動物に高脂肪・低カルシウムの飼料を摂取さ
せると大腸癌を進行させ易い腸内環境が誘導されるとい
う報告がなされている(Newmark,H.L., Lipkin,M. and M
aheshwari,N.,Journal of National Cancer Institute,
vol.82, pp.491-496, 1990) 。These rats were divided into three groups of eight animals per group while taking into consideration that the weights were equal between the groups, and the experimental feeds shown in Table 3 were freely taken for 15 days. In addition, ion-exchanged water was also freely taken. The fat content of the control feed and the experimental feed was determined using the standard feed (American Institute of Nut).
rition, Journal of Nutrition, vol.107, pp.1340-134
8, 1977) and the amount of calcium is 1/5.
In addition, it has been reported that ingestion of high-fat and low-calcium feed to experimental animals induces an intestinal environment that facilitates colorectal cancer (Newmark, HL, Lipkin, M. and M.
aheshwari, N., Journal of National Cancer Institute,
vol.82, pp.491-496, 1990).
【００１５】[0015]
【表３】 ─────────────────────────────────── 対照飼料 実験飼料１ 実験飼料２ ─────────────────────────────────── カゼイン 20 20 20 （重量％） ココナッツ油 18 18 18 コーン油 2 2 2 グルコース 50 49 49 菌体粉末 − 1 1 セルロース 5 5 5 塩類混合 3.5 3.5 3.5 ビタミン混合 1 1 1 ＤＬ−メチオニン 0.3 0.3 0.3 重酒石酸コリン 0.2 0.2 0.2 ───────────────────────────────────[Table 3] Control feed Experimental feed 1 Experimental feed 2 ──────────────────────────────── Casein 20 20 20 (% by weight) Coconut oil 18 18 18 Corn oil 2 2 2 Glucose 50 49 49 Cell powder −11 Cellulose 55 5 Salt mixture 3.5 3.5 3.5 Vitamin mixture 1 1 1 DL-methionine 0.3 0.3 0.3 Choline bitartrate 0.2 0.2 0.2 ────────────── ─────────────────────
【００１６】なお、実験飼料１に配合する菌体粉末は、
参考例１で得られたラクトバチルス・アシドフィルス(L
actobacillus acidophilus) SBT-2062 (FERM P-10730)
の菌体粉末とし、実験飼料２に配合する菌体粉末は、参
考例２で得られたビフィドバクテリウム・ロンガム(Bif
idobacterium longum) SBT-2928 (FERM P-10657) の菌
体粉末とした。また、対照飼料及び実験飼料に配合する
塩類混合の組成を表４に、ビタミン混合の組成を表５に
それぞれ示す。The bacterial powder to be mixed with the experimental feed 1 is as follows:
Lactobacillus acidophilus (L) obtained in Reference Example 1
actobacillus acidophilus) SBT-2062 (FERM P-10730)
Of the Bifidobacterium longum (Bif) obtained in Reference Example 2 was used.
idobacterium longum ) SBT-2928 (FERM P-10657). Table 4 shows the composition of the salt mixture mixed with the control feed and the experimental feed, and Table 5 shows the composition of the vitamin mixture.
【００１７】[0017]
【表４】 ────────────────────────── リン酸カルシウム・２水和物 12.3 (重量％) 塩化ナトリウム 7.4 塩化カリウム 7.7 炭酸水素カリウム 10.0 硫酸カリウム 5.2 酸化マグネシウム 2.4 硫酸マンガン・５水和物 0.73 硫酸第一鉄・７水和物 0.51 炭酸亜鉛 0.16 炭酸銅・水酸化銅・水和物 0.03 セレン酸ナトリウム・５水和物 0.001 ヨウ素酸カリウム 0.001 クロム硫酸カリウム・１２水和物 0.055 ──────────────────────────[Table 4] カ ル シ ウ ム Calcium phosphate dihydrate 12.3 (% by weight) Sodium chloride 7.4 Potassium chloride 7.7 Potassium hydrogen carbonate 10.0 potassium sulfate 5.2 magnesium oxide 2.4 manganese sulfate pentahydrate 0.73 ferrous sulfate heptahydrate 0.51 zinc carbonate 0.16 copper carbonate copper hydroxide hydrate 0.03 sodium selenate pentahydrate 0.001 iodic acid Potassium 0.001 Potassium chromium sulfate dodecahydrate 0.055 ──────────────────────────
【００１８】上記した組成にショ糖を加え、塩類混合全
体を 100％とする。Sucrose is added to the above composition to make the whole salt mixture 100%.
【表５】 ─────────────────────── ビタミンＥ・アセテート 750 IU/100g ビタミンＫ3 5 mg/100g ビタミンＢ1 60 mg/100g ビタミンＢ2 60 mg/100g ビタミンＢ6 70 mg/100g ビタミンＢ12 0.1 mg/100g Ｄ−ビオチン 2 mg/100g 葉酸 20 mg/100g パントテン酸カルシウム 160 mg/100g ニコチン酸 300 mg/100g ───────────────────────[Table 5] ─────────────────────── Vitamin E / acetate 750 IU / 100g Vitamin K 3 5mg / 100g Vitamin B 1 60mg / 100g Vitamin B 2 60 mg / 100 g Vitamin B 6 70 mg / 100 g Vitamin B 12 0.1 mg / 100 g D-biotin 2 mg / 100 g Folic acid 20 mg / 100 g Calcium pantothenate 160 mg / 100 g Nicotinic acid 300 mg / 100 g ───── ──────────────────
【００１９】上記した組成にショ糖を加え、ビタミン混
合全体を100gとする。飼育終了後、エーテル麻酔下でラ
ットを解剖して盲腸を摘出して盲腸内容物を回収し、そ
の重量を測定した。また、この盲腸内容物中の酪酸濃度
を測定した。なお、15日間の飼育期間中、各群共に体重
増加量及び摂取カロリーに有意差は認められなかった。Sucrose is added to the above composition to make the total vitamin mixture 100 g. After the rearing, the rats were dissected under ether anesthesia, the cecum was excised, the contents of the cecum were collected, and the weight was measured. The butyric acid concentration in the cecal contents was measured. During the breeding period of 15 days, no significant difference was observed in the weight gain and the calorie intake of each group.
【００２０】（２）盲腸内容物中の酪酸濃度の測定 回収した盲腸内容物に９倍重量の蒸留水を加えて混合
し、酪酸を抽出した後、４℃で遠心分離 (10,000×g 、
20分間) を行い水溶性画分を分離した。そして、この水
溶性画分を0.45μm のフィルターに通液した後、カルボ
ン酸分析計 (S-14型、東京理科器械) で酪酸濃度を測定
した。なお、盲腸内容物中の酪酸濃度は、以下の式によ
り算出した。 盲腸内容物中の酪酸濃度(mg/盲腸内容物）＝酪酸濃度
（μg/ml) ×10÷1,000×盲腸内容物重量(g)(2) Measurement of butyric acid concentration in cecal contents The recovered cecal contents were mixed with 9 times by weight of distilled water to extract butyric acid, and then centrifuged at 4 ° C. (10,000 × g,
(20 minutes) to separate the water-soluble fraction. After passing the water-soluble fraction through a 0.45 μm filter, the butyric acid concentration was measured with a carboxylic acid analyzer (S-14, Tokyo Rikakiki). The butyric acid concentration in the cecal contents was calculated by the following equation. Butyric acid concentration in cecal contents (mg / cecal contents) = butyric acid concentration (μg / ml) × 10 ÷ 1,000 × weight of cecal contents (g)
【００２１】[0021]
【表６】 ────────────────────────── 対照飼料投与群 0.86±0.11 (mg/盲腸内容物) 実験飼料１投与群 1.46±0.12* 実験飼料２投与群 1.19±0.10* ────────────────────────── 数値は、平均値±標準誤差を示す。 * は、対照飼料投与群との間に有意差あり (危険率５％以下) を示す。[Table 6] ────────────────────────── Control feed administration group 0.86 ± 0.11 (mg / cecal content) Experimental feed 1 administration group 1.46 ± 0.12 * Experimental feed 2 administration group 1.19 ± 0.10 *数 値 Numerical values indicate mean ± standard error. * Indicates that there is a significant difference (risk rate 5% or less) from the control feed administration group.
【００２２】ラクトバチルス・アシドフィルス(Lactoba
cillus acidophilus)又はビフィドバクテリウム・ロン
ガム(Bifidobacterium longum) の菌体粉末を配合した
実験飼料投与群では、対照飼料投与群に比べ、１，２−
ジメチルヒドラジン・２塩酸を注射することにより大腸
癌を発病し易い遺伝的素因を誘導させると共に、高脂肪
・低カルシウム飼料を摂取させることにより大腸癌を進
行させ易い腸内環境を誘導したラットの盲腸内容物に含
まれている酪酸濃度が有意に上昇している。この結果の
ように、ラクトバチルス・アシドフィルス(Lactobacill
us acidophilus)及びビフィドバクテリウム・ロンガム
(Bifidobacterium longum) の菌体には、腸内酪酸濃度
上昇促進作用があることが認められた。Lactobacillus acidophilus (Lactoba
cillus acidophilus) or Bifidobacterium longum (Bifidobacterium longum ) in the experimental diet-administered group, compared with the control diet-administered group, 1,2-.
Injection of dimethylhydrazine dihydrochloride induces a genetic predisposition to develop colorectal cancer, and ingests a high-fat, low-calcium diet to induce an intestinal environment that facilitates colorectal cancer. The concentration of butyric acid contained in the contents is significantly increased. As shown in this result, Lactobacillus acidophilus (Lactobacill
us acidophilus) and Bifidobacterium longum
(Bifidobacterium longum ) was found to have an intestinal butyric acid concentration increase promoting effect.
【００２３】[0023]
【発明の実施の形態】本発明は、ラクトバチルス・アシ
ドフィルス(Lactobacillus acidophilus)やビフィドバ
クテリウム・ロンガム(Bifidobacterium longum) の菌
体を有効成分とする腸内酪酸濃度上昇促進剤である。ま
た、本発明は、ラクトバチルス・アシドフィルス(Lacto
bacillus acidophilus)及び／又はビフィドバクテリウ
ム・ロンガム(Bifidobacterium longum) の菌体を配合
して腸内酪酸濃度上昇促進作用を賦与した飲食品及び飼
料である。BEST MODE FOR CARRYING OUT THE INVENTION The present invention relates to an agent for increasing intestinal butyric acid concentration, which comprises as an active ingredient cells of Lactobacillus acidophilus and Bifidobacterium longum. It is. The present invention also relates to Lactobacillus acidophilus (Lacto
The present invention relates to foods and drinks and feeds which contain cells of bacillus acidophilus and / or Bifidobacterium longum to impart an action to promote intestinal butyric acid concentration.
【００２４】このラクトバチルス・アシドフィルス(Lac
tobacillus acidophilus)やビフィドバクテリウム・ロ
ンガム(Bifidobacterium longum) の菌体については、
培養基として合成培地等の培地を使用して培養した後、
遠心分離等の操作により菌体を回収し、必要に応じて、
菌体の洗浄や凍結乾燥等の処理を行い、本発明の腸内酪
酸濃度上昇促進剤の有効成分として使用される。そし
て、このようにして得られた菌体は、そのままの状態
で、又は、乳糖等の賦形剤を加えて粉剤、錠剤、丸剤、
カプセル剤、顆粒剤として、腸内酪酸濃度上昇促進剤と
することができる。この腸内酪酸濃度上昇促進剤は経口
的に投与することができる。また、例えば、清涼飲料
水、果汁飲料、発酵飲料、ゼリー、アイスクリーム、ガ
ムやキャンディー等の菓子類等各種飲食品や飼料にこれ
らの菌体を配合することにより、腸内酪酸濃度上昇促進
作用が賦与された飲食品や飼料とすることもできる。な
お、本発明の有効成分であるラクトバチルス・アシドフ
ィルス(Lactobacillus acidophilus)やビフィドバクテ
リウム・ロンガム(Bifidobacterium longum) 菌体の好
ましい摂取量は、一日当たり菌体粉末として 0.5〜5gで
あり、１日１回〜数回に分けて摂取すると良い。The Lactobacillus acidophilus (Lac
tobacillus acidophilus) and Bifidobacterium longum (Bifidobacterium longum )
After culturing using a medium such as a synthetic medium as a culture medium,
Collect the cells by operations such as centrifugation and, if necessary,
The cells are washed, lyophilized, and the like, and used as an active ingredient of the intestinal butyric acid concentration increase promoter of the present invention. And the cells obtained in this way, as is, or by adding excipients such as lactose, powders, tablets, pills,
As capsules and granules, it can be used as an intestinal butyric acid concentration increase promoter. This intestinal butyric acid concentration increase promoter can be administered orally. Further, for example, by adding these cells to various foods and drinks and feeds such as soft drinks, fruit juice drinks, fermented drinks, jellies, ice creams, gums and candies, and the like, the intestinal butyric acid concentration increase promoting action. Or feed or feed to which is added. The preferred intake of Lactobacillus acidophilus (Lactobacillus acidophilus) or Bifidobacterium longum (Bifidobacterium longum ) cells, which is an active ingredient of the present invention, is 0.5 to 5 g as a cell powder per day. It is advisable to take once to several times a day.
【００２５】[0025]
【実施例１】参考例１で得られたラクトバチルス・アシ
ドフィルス(Lactobacillus acidophilus)又は参考例２
で得られたビフィドバクテリウム・ロンガム(Bifidobac
terium longum) の菌体粉末 40gに、乳糖900gとコーン
スターチ574gを加えてＶ型混合機で混合し、混合粉末を
得た。そして、ヒドロキシプロピルセルロース 16gに滅
菌精製水 150mlを加えて撹拌溶解した溶液と共にこの混
合粉末を双軸練合機で練合し、押し出し造粒機で造粒し
た後、通気乾燥機で60℃、30分間乾燥することにより整
粒し、顆粒状の腸内酪酸濃度上昇促進剤1,480gを製造し
た。Example 1 Lactobacillus acidophilus obtained in Reference Example 1 or Reference Example 2
Bifidobacterium longum (Bifidobac
terium longum ) was added to lactose (900 g) and corn starch (574 g) and mixed with a V-type mixer to obtain a mixed powder. Then, this mixed powder was kneaded with a twin-screw kneader together with a solution obtained by adding 150 ml of sterile purified water to 16 g of hydroxypropylcellulose and stirring and dissolving, granulated by an extrusion granulator, and then dried at 60 ° C. by a through-air drier. After drying for 30 minutes, the granules were sized to produce 1,480 g of a granular intestinal butyric acid concentration increase promoter.
【００２６】[0026]
【実施例２】参考例１で得られたラクトバチルス・アシ
ドフィルス(Lactobacillus acidophilus)又は参考例２
で得られたビフィドバクテリウム・ロンガム(Bifidobac
terium longum) の菌体粉末500g、リンゴ冷凍濃縮果汁
25kg、グラニュー糖92kg、リンゴ酸 2.5kg、クエン酸
0.5kg、アップルアロマ３kg、エッセンス１kgに水 900k
gを加えて混合溶解することにより、腸内酪酸濃度上昇
促進作用が賦与された清涼飲料水 1,000kgを製造した。Example 2 Lactobacillus acidophilus obtained in Reference Example 1 or Reference Example 2
Bifidobacterium longum (Bifidobac
terium longum ), 500 g of bacterial cell powder, frozen apple juice
25 kg, granulated sugar 92 kg, malic acid 2.5 kg, citric acid
0.5kg, apple aroma 3kg, essence 1kg and water 900k
g was added and mixed and dissolved to produce 1,000 kg of soft drink having an intestinal butyric acid concentration increase promoting effect.
【００２７】[0027]
【実施例３】参考例１で得られたラクトバチルス・アシ
ドフィルス(Lactobacillus acidophilus)又は参考例２
で得られたビフィドバクテリウム・ロンガム(Bifidobac
terium longum) の菌体粉末１kg、大豆粕 120kg、脱脂
粉乳 140kg、大豆油40kg、コーン油20kg、パーム油 280
kg、トウモロコシ澱粉 149kg、小麦粉90kg、フスマ20k
g、ビタミン混合物90kg、ミネラル混合物20kg及びセル
ロース30kgを混合して、腸内酪酸濃度上昇促進作用が賦
与されたイヌ飼育用飼料 (ドッグフード)1,000kgを製造
した。Example 3 Lactobacillus acidophilus obtained in Reference Example 1 or Reference Example 2
Bifidobacterium longum (Bifidobac
terium longum ) 1 kg, soybean meal 120 kg, skim milk powder 140 kg, soybean oil 40 kg, corn oil 20 kg, palm oil 280
kg, corn starch 149 kg, flour 90 kg, bran 20 k
g, 90 kg of a vitamin mixture, 20 kg of a mineral mixture, and 30 kg of cellulose were mixed to produce 1,000 kg of a dog breeding feed (dog food) having an effect of promoting an increase in intestinal butyric acid concentration.
【００２８】[0028]
【発明の効果】ラクトバチルス・アシドフィルス(Lacto
bacillus acidophilus)やビフィドバクテリウム・ロン
ガム(Bifidobacterium longum) の菌体には、腸内の酪
酸濃度を上昇促進させる作用があるので、これらの菌体
を医薬や飲食品、あるいは飼料として摂取させることに
より、腸内酪酸濃度の低下に由来する大腸癌の発病を抑
制あるいは予防する効果が期待できる。According to the present invention, Lactobacillus acidophilus (Lacto
The cells of bacillus acidophilus) and Bifidobacterium Ron <br/> gum (Bifidobacterium longum), there is a function to increase promotion butyrate concentration in the intestine, pharmaceutical and food products these cells, or Ingestion as a feed can be expected to have the effect of suppressing or preventing the onset of colorectal cancer caused by a decrease in intestinal butyric acid concentration.
Claims (3)
bacillus acidophilus)及び／又はビフィドバクテリウ
ム・ロンガム(Bifidobacterium longum) の菌体を有効
成分とする腸内酪酸濃度上昇促進剤。[1] Lactobacillus acidophilus ( Lacto)
bacillus acidophilus) and / or Bifidobacterium longum (intestinal butyrate concentration increased promoter having for an active ingredient to cells of Bifidobacterium longum).
bacillus acidophilus)及び／又はビフィドバクテリウ
ム・ロンガム(Bifidobacterium longum) の菌体を配合
して腸内酪酸濃度上昇促進作用を賦与した飲食品。2. Lactobacillus acidophilus ( Lacto)
A food or drink comprising a cell of bacillus acidophilus and / or Bifidobacterium longum to impart an intestinal butyric acid concentration increase promoting effect.
bacillus acidophilus)及び／又はビフィドバクテリウ
ム・ロンガム(Bifidobacterium longum) の菌体を配合
して腸内酪酸濃度上昇促進作用を賦与した飼料。3. Lactobacillus acidophilus ( Lacto)
bacillus acidophilus) and / or Bifidobacterium longum (Bifidobacterium longum) the cells and mixed feeds which endow intestinal butyrate concentration increase promoting effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8263731A JPH1084909A (en) | 1996-09-13 | 1996-09-13 | Intestinal butyric acid concentration increase accelerating agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8263731A JPH1084909A (en) | 1996-09-13 | 1996-09-13 | Intestinal butyric acid concentration increase accelerating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1084909A true JPH1084909A (en) | 1998-04-07 |
Family
ID=17393521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8263731A Pending JPH1084909A (en) | 1996-09-13 | 1996-09-13 | Intestinal butyric acid concentration increase accelerating agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1084909A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001158743A (en) * | 1999-12-02 | 2001-06-12 | Wakamoto Pharmaceut Co Ltd | Lactobacillus-containing composition, medicament and food |
| JP2002058434A (en) * | 2000-08-21 | 2002-02-26 | Nisshin Shiryo Kk | Feed additive for animal |
| JP2002058432A (en) * | 2000-08-21 | 2002-02-26 | Nisshin Shiryo Kk | Feed additive |
| WO2002045732A1 (en) * | 2000-12-05 | 2002-06-13 | Kabushiki Kaisha Yakult Honsha | Proliferation promoters for enteric bifidobacteria |
| JP2002537861A (en) * | 1999-03-10 | 2002-11-12 | マーズ ユー ケー リミテッド | Pet food products containing coconut endosperm fiber |
| JP2006519759A (en) * | 2002-12-05 | 2006-08-31 | ダニスコ・フランス | Bacterial composition and use thereof |
| JP2008195673A (en) * | 2007-02-14 | 2008-08-28 | Nippon Meat Packers Inc | Life prolongation-effective substance, and infection-protecting effect and vaccine effect-promoting substance, construct for assaying the above substances, and application of the above substances |
| JP2012180373A (en) * | 2012-06-13 | 2012-09-20 | Snow Brand Milk Products Co Ltd | Prevention, improvement, therapeutic agent of metabolic error disease according to aging |
| JP2014055194A (en) * | 2013-12-26 | 2014-03-27 | Snow Brand Milk Products Co Ltd | Preventive, improving, and therapeutic agent for metabolic disorder with aging |
| KR20160138056A (en) | 2014-03-28 | 2016-12-02 | 가부시키가이샤 야쿠르트 혼샤 | Butyric acid-producing microbe and use thereof |
| WO2022163323A1 (en) * | 2021-01-26 | 2022-08-04 | 雪印メグミルク株式会社 | Composition for improving joint function |
-
1996
- 1996-09-13 JP JP8263731A patent/JPH1084909A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537861A (en) * | 1999-03-10 | 2002-11-12 | マーズ ユー ケー リミテッド | Pet food products containing coconut endosperm fiber |
| JP4970656B2 (en) * | 1999-03-10 | 2012-07-11 | マーズ ユー ケー リミテッド | Pet food products containing coconut endosperm fiber |
| JP4603116B2 (en) * | 1999-12-02 | 2010-12-22 | わかもと製薬株式会社 | Lactic acid bacteria-containing composition, medicine and food |
| JP2001158743A (en) * | 1999-12-02 | 2001-06-12 | Wakamoto Pharmaceut Co Ltd | Lactobacillus-containing composition, medicament and food |
| JP2002058434A (en) * | 2000-08-21 | 2002-02-26 | Nisshin Shiryo Kk | Feed additive for animal |
| JP2002058432A (en) * | 2000-08-21 | 2002-02-26 | Nisshin Shiryo Kk | Feed additive |
| WO2002045732A1 (en) * | 2000-12-05 | 2002-06-13 | Kabushiki Kaisha Yakult Honsha | Proliferation promoters for enteric bifidobacteria |
| JP2011184456A (en) * | 2002-12-05 | 2011-09-22 | Danisco As | Bacterial composition and use of the same |
| JP2006519759A (en) * | 2002-12-05 | 2006-08-31 | ダニスコ・フランス | Bacterial composition and use thereof |
| JP2014159476A (en) * | 2002-12-05 | 2014-09-04 | Dupont Nutrition Biosciences Aps | Bacterial composition and its use |
| JP2008195673A (en) * | 2007-02-14 | 2008-08-28 | Nippon Meat Packers Inc | Life prolongation-effective substance, and infection-protecting effect and vaccine effect-promoting substance, construct for assaying the above substances, and application of the above substances |
| JP2012180373A (en) * | 2012-06-13 | 2012-09-20 | Snow Brand Milk Products Co Ltd | Prevention, improvement, therapeutic agent of metabolic error disease according to aging |
| JP2014055194A (en) * | 2013-12-26 | 2014-03-27 | Snow Brand Milk Products Co Ltd | Preventive, improving, and therapeutic agent for metabolic disorder with aging |
| KR20160138056A (en) | 2014-03-28 | 2016-12-02 | 가부시키가이샤 야쿠르트 혼샤 | Butyric acid-producing microbe and use thereof |
| US10293004B2 (en) | 2014-03-28 | 2019-05-21 | Kabushiki Kaisha Yakult Honsha | Butyrate-producing bacterium and use thereof |
| WO2022163323A1 (en) * | 2021-01-26 | 2022-08-04 | 雪印メグミルク株式会社 | Composition for improving joint function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1513541B1 (en) | Method for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract | |
| KR101992537B1 (en) | Novel Lactobacillus sakei and compositions comprising the same | |
| WO2021149663A1 (en) | Composition | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| JP2020164493A (en) | Composition for suppressing muscle inflammation and composition for suppressing intestinal inflammation | |
| JPH1084909A (en) | Intestinal butyric acid concentration increase accelerating agent | |
| JPH09194384A (en) | Mineral absorption accelerating agent | |
| JP2532911B2 (en) | Composition for promoting intestinal colonization of useful bacteria | |
| EP3431090A1 (en) | Proliferative agent for bacteria of genus faecalibacterium | |
| US20130004475A1 (en) | Agent for increasing bifidobacteria and reducing the decrease of bifidobacteria in large intestine | |
| US8007783B2 (en) | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine | |
| JPWO2019035486A1 (en) | Glycemic spike inhibitor, food, and method for producing blood glucose spike inhibitor | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| KR20220008218A (en) | Composition for preventing or treating inflammatory bowel diseases | |
| TW201818828A (en) | Composition for inhibiting reduction of lactic acid bacteria of genus lactobacillus in intestine | |
| AU2017287987A1 (en) | Cartilage regeneration facilitating composition | |
| JP7266580B2 (en) | Composition for infants for prevention of diseases caused by hyperglycemia after school age | |
| JP4852681B2 (en) | Intestinal cytolytic activity inhibitor | |
| JP3390613B2 (en) | Bifidus factor activity enhancer / stabilizer | |
| JP4721684B2 (en) | Oral composition containing difructose anhydride | |
| JP2020132621A (en) | Composition for skin gas emission control | |
| JPWO2019180964A1 (en) | FGF21 secretagogue composition | |
| EP4260905A1 (en) | Composition containing acidipropionibacterium spp. or treated product thereof | |
| JP2021182889A (en) | Composition for improving pulmonary functions, and composition for preventing, treating or alleviating pulmonary diseases | |
| JP2024152695A (en) | Composition and method for growing bifidobacteria, and composition and method for increasing lactic acid and/or pyruvic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040409 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040608 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041012 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20041130 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20050902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070312 |